IDXX · IDEXX Laboratories
27 filings
IDXX 10-K Annual Reports
IDEXX Laboratories - 27 annual reports
IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.
- 8-K · Jan 29, 2016
- 8-K · Feb 12, 2016
- 10-K · Feb 17, 2016
- 8-K · Apr 29, 2016
- 10-Q · Apr 29, 2016
- 8-K · May 6, 2016
- 10-Q · Aug 2, 2016
- 8-K · Aug 2, 2016
- 8-K · Oct 19, 2016
- 8-K · Nov 1, 2016
- 10-Q · Nov 1, 2016
- 8-K · Nov 15, 2016
- 8-K · Feb 2, 2017
- 8-K/A · Feb 16, 2017
- 10-K · Feb 17, 2017
- 8-K · Feb 21, 2017
- 8-K/A · Feb 22, 2017
- 10-Q · Apr 28, 2017
- 8-K · Apr 28, 2017
- 8-K · May 5, 2017
- 8-K · Jul 17, 2017
- 8-K · Aug 1, 2017
- 10-Q · Aug 1, 2017
- 8-K/A · Oct 6, 2017
- 8-K/A · Oct 23, 2017
- 10-Q · Oct 31, 2017
- 8-K · Oct 31, 2017
- 8-K · Dec 12, 2017
- 8-K · Jan 5, 2018
- 8-K · Feb 1, 2018
- 10-K · Feb 16, 2018
- 8-K · Feb 20, 2018
- 8-K · May 4, 2018
- 10-Q · May 4, 2018
- 8-K · May 15, 2018
- 8-K · Jun 15, 2018
- 10-Q · Aug 1, 2018
- 8-K · Aug 1, 2018
- 8-K · Nov 1, 2018
- 10-Q · Nov 1, 2018
- 8-K · Feb 1, 2019
- 10-K · Feb 15, 2019
- 8-K · Mar 15, 2019
- 10-Q · May 1, 2019
- 8-K · May 1, 2019
- 8-K · May 13, 2019
- 8-K · Jul 1, 2019
- 8-K · Jul 18, 2019
- 8-K · Jul 24, 2019
- 10-Q · Aug 1, 2019
- 8-K · Aug 1, 2019
- 8-K · Aug 5, 2019
- 8-K · Oct 24, 2019
- 8-K · Oct 31, 2019
- 10-Q · Oct 31, 2019
- 8-K · Jan 31, 2020
- 10-K · Feb 14, 2020
- 8-K · Mar 27, 2020
- 8-K · Apr 8, 2020
- 8-K · Apr 16, 2020
- 10-Q · Apr 30, 2020
- 8-K · Apr 30, 2020
- 8-K · May 11, 2020
- 8-K · Jul 31, 2020
- 10-Q · Jul 31, 2020
- 10-Q · Oct 29, 2020
- 8-K · Oct 29, 2020
- 8-K · Nov 12, 2020
- 8-K · Feb 2, 2021
- 8-K · Feb 10, 2021
- 10-K · Feb 12, 2021
- 10-Q · May 4, 2021
- 8-K · May 4, 2021
- 8-K · May 18, 2021
- 10-Q · Jul 30, 2021
- 8-K · Jul 30, 2021
- 10-Q · Nov 2, 2021
- 8-K · Nov 2, 2021
- 8-K · Dec 9, 2021
- 8-K · Feb 2, 2022
- 10-K · Feb 16, 2022
- 10-Q · May 4, 2022
- 8-K · May 4, 2022
- 8-K · May 13, 2022
- 8-K · Jun 14, 2022
- 8-K · Jul 15, 2022
- 10-Q · Aug 2, 2022
- 8-K · Aug 2, 2022
- 8-K · Oct 21, 2022
- 8-K · Nov 1, 2022
- 10-Q · Nov 1, 2022
- 8-K · Feb 6, 2023
- 10-K · Feb 16, 2023
- 10-Q · May 2, 2023
- 8-K · May 2, 2023
- 8-K · May 19, 2023
- 8-K · Jul 12, 2023
- 10-Q · Aug 1, 2023
- 8-K · Aug 1, 2023
- 10-Q · Nov 1, 2023
- 8-K · Nov 1, 2023
- 8-K · Dec 7, 2023
- 8-K · Feb 5, 2024
- 10-K · Feb 22, 2024
- 10-Q · May 1, 2024
- 8-K · May 1, 2024
- 8-K · May 10, 2024
- 8-K · Aug 6, 2024
- 10-Q · Aug 6, 2024
- 10-Q · Oct 31, 2024
- 8-K/A · Oct 31, 2024
- 8-K · Oct 31, 2024
- 8-K · Nov 6, 2024
- 8-K · Nov 12, 2024
- 8-K · Nov 21, 2024
- 8-K · Dec 9, 2024
- 8-K · Dec 12, 2024
- 8-K · Feb 3, 2025
- 8-K · Feb 14, 2025
- 10-K · Feb 21, 2025
- 10-Q · May 1, 2025
- 8-K · May 1, 2025
- 8-K · May 9, 2025
- 8-K · Jul 10, 2025
- 10-Q · Aug 4, 2025
- 8-K · Aug 4, 2025
- 8-K · Oct 7, 2025
- 10-Q · Nov 3, 2025
- 8-K · Nov 3, 2025
- 8-K · Nov 13, 2025
- 8-K · Jan 13, 2026
- 8-K · Feb 2, 2026
- 8-K · Feb 13, 2026
- 10-K · Feb 20, 2026
- 8-K · Mar 26, 2026
- 10-Q · May 5, 2026
- 8-K · May 5, 2026
- 8-K · May 15, 2026
- 10-Q · Aug 4, 2026
- 8-K · Aug 4, 2026
- 8-K · Nov 2, 2026
- 10-Q · Nov 2, 2026
- 2025Feb 20, 2026
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2025
IDEXX Laboratories (IDXX) closed 2025 with record results: revenue rose 10.4% reported (9.6% organic) to $4.30 billion, and income from operations grew 20.5% to $1.36 billion, with operating margin expanding about 260 basis points to 31.6%. Net income reached $1.06 billion and diluted EPS was $13.08, up from $10.67 in 2024. Growth was led by the Companion Animal Group (CAG), where recurring diagnostic revenue (about 79% of consolidated revenue) rose 8.9%, driven by IDEXX VetLab consumables (+14.8%) and reference laboratory services (+6.6%). The new IDEXX inVue Dx cytology analyzer drove a 51.8% increase in instrument revenue. Gross margin improved to 61.8% and the installed base of premium instruments grew about 12%. The filing also flags headwinds that investors should weigh. Management expects U.S. same-store clinical visits to decline roughly 2% again in 2026, reflecting veterinary capacity constraints and macroeconomic pressure, and it projects a higher 2026 effective tax rate of about 21.3%. Operating cash flow was strong at $1.18 billion, but free cash flow after $125 million of capex was reduced by a roughly $80 million litigation payment. Capital returns were heavy: about $1.2 billion was spent repurchasing about 2.4 million shares, and the company guided to a further 1% to 2% reduction in diluted shares in 2026. Leverage remains modest, with a gross debt to Adjusted EBITDA ratio of 0.54x against a 3.5x covenant. Management also announced a planned CEO transition in May 2026. Risk factors emphasize concentration in a few key suppliers, including Ortho for Catalyst chemistry slides, along with rising competition from Mars-owned and Zoetis businesses, consolidation of corporate veterinary hospitals, and evolving AI, PFAS, and data-privacy regulation. Management reports that its internal controls over financial reporting were effective and that PwC issued an unqualified audit opinion.
- 2024Feb 21, 2025
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2024
IDEXX Laboratories' FY2024 10-K shows a company still growing at a solid clip with strong profitability, though 2025 guidance points to a slower top line. Revenue rose 6.5% reported (6.4% organic) to $3.90 billion, driven mainly by price realization and recurring Companion Animal Group (CAG) diagnostics revenue, which made up about 80% of consolidated revenue. Gross margin expanded 120 basis points to 61.0%, and operating income grew 2.8% to $1.13 billion. Diluted EPS was $10.67, up from $10.06, and net income reached $887.9 million. Results were held back by a $61.5 million charge tied to an ongoing royalty litigation matter, which the company has now accrued at $89.0 million. Cash generation remained strong, with operating cash flow of $929.0 million. Management returned capital aggressively: $837.0 million in buybacks in 2024, with roughly $1.5 billion of repurchases planned for 2025. Cash fell to $288.3 million, and total debt is modest, with a gross debt to Adjusted EBITDA ratio of 0.65x and a net debt ratio of 0.44x, well inside the 3.5x covenant. Near-term maturities include a $250 million term loan due October 2025 and senior notes due in 2025 and 2026. Looking ahead, management expects U.S. same-store clinical visits to decline in 2025, reflecting sector capacity constraints and macroeconomic headwinds. Foreign exchange is also a meaningful drag, with about $80 million of expected revenue impact and $0.21 of EPS headwind at current rates, partly offset by hedging. The effective tax rate is projected to rise to about 21.5%. Overall, investors are weighing durable recurring revenue and strong capital returns against softer visit trends and a stronger dollar.
- 2023Feb 22, 2024
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2023
IDEXX Laboratories' FY2023 10-K shows a strong year driven by pricing and recurring diagnostic revenue. Total revenue rose 8.7% reported (8.8% organic) to $3.66 billion, with Companion Animal Group (CAG) growing 9.6% to $3.35 billion and recurring CAG Diagnostics revenue reaching $2.94 billion, about 80% of consolidated revenue. Gross margin expanded 30 bps to 59.8%, and operating income rose 22.1% to $1.10 billion (30.0% of revenue), helped by a $16 million customer contract resolution gain and lower R&D after a prior-year $84 million technology license charge. Net income was $845 million, and diluted EPS was $10.06, up from $8.03. The balance sheet and cash flow improved meaningfully. Operating cash flow was $906.5 million, up from $543.0 million, and cash ended at $453.9 million versus $112.5 million a year earlier. Gross debt to Adjusted EBITDA was 0.74x and net debt to Adjusted EBITDA was 0.39x, well inside the 3.5x covenant. The company repurchased only $71.9 million of stock in 2023, versus $819.7 million in 2022, and it has never paid a cash dividend. Management's 2024 outlook includes a projected effective tax rate of about 22%, capital expenditures of about $180 million, and an approximately $77 million acquisition closed on February 1, 2024. Key risks flagged in the filing include intensifying competition, consolidation of veterinary practices into corporate groups and buying consortiums, sole-source supplier dependence (notably Ortho for chemistry slides), AI-related regulatory and reputational exposure, and a pending state supreme court ruling on a royalty lawsuit with a $50 million claim against which $27.5 million has been accrued. U.S. same-store clinical visits declined about 0.5% in 2023, so growth relied on pricing and diagnostic utilization rather than visit volume.
- 2022Feb 16, 2023
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2022
IDEXX Laboratories' FY2022 10-K shows a company that grew revenue 4.7% reported (7.4% organic) to $3.37 billion, with diluted EPS of $8.03, down from $8.60 in 2021. The decline in earnings reflects a $65 million in-process R&D charge from two IP licensing arrangements, higher R&D spend overall (R&D rose to 7.6% of revenue from 5.0%), a higher effective tax rate of 21.0% versus 17.5%, and a 3.4% currency headwind to reported revenue growth. Operating income fell 3.6% to $898.8 million, and operating margin compressed from 29.0% to 26.7%. The Companion Animal Group (CAG) drives the business, generating about 91% of revenue, with recurring diagnostic revenue of roughly 79% of consolidated revenue. Growth was led by price realization and higher VetLab consumable and reference laboratory volumes, while Water grew 6.3% and LPD declined 9.8% on weaker China swine testing. Cash flow from operations fell to $543 million from $756 million, driven by heavier inventory build and other working-capital changes, and the company spent $820 million on share repurchases, funded in part by a $432 million increase in credit facility borrowings. Leverage rose meaningfully: total debt including the revolver reached about $1.35 billion, a gross debt to Adjusted EBITDA ratio of 1.27x and net leverage of 1.17x, well inside the 3.5x covenant. Management guides to a roughly 22% effective tax rate for 2023, a $180 million capex plan, and a stronger dollar headwind of about $0.23 per share in 2023. A pending $27.5 million accrual related to an ongoing royalty lawsuit and the possible impact of the Maine PFAS rules are the main contingent items flagged for investors.
- 2021Feb 16, 2022
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2021
IDEXX Laboratories' FY2021 10-K shows a strong year driven by its Companion Animal Group (CAG), which generated 90% of consolidated revenue. Total revenue rose 18.8% reported (16.4% organic) to $3.215 billion, gross margin expanded 80 bps to 58.8%, and operating income grew 34.2% to $932.0 million, or 29.0% of revenue. Diluted EPS was $8.60, up from $6.71. Growth was led by CAG Diagnostics recurring revenue (up 19.9% reported), which reflects rebounding clinical visits, higher diagnostic utilization per visit, and pricing, partly offset by weakness in Livestock, Poultry and Dairy (LPD) from lower African Swine Fever testing demand in China. Management expects the LPD and OPTI COVID-19 testing revenue to decline in 2022. Cash generation remained solid, with operating cash flow of $755.5 million. The company deployed significant capital: $755.5 million in open-market buybacks (about 1.3 million shares), $173.4 million in acquisitions (notably ezyVet and Vet Radar software), and $119.5 million in capex. Cash fell to $144.5 million, and total debt rose to about $924 million including a $73.5 million revolver draw. Gross debt to Adjusted EBITDA was 0.86x and net debt to Adjusted EBITDA was 0.73x, well inside the 3.5x covenant. The company also extended its $1 billion revolving credit facility to December 2026. Key watch items include a 2022 effective tax rate guided to about 22% (up from 17.5%), an approximately $55 million revenue headwind from a stronger U.S. dollar in 2022, a 2022 capex plan of roughly $180 million, and an ongoing royalty litigation with a $27.5 million accrual against a claim of about $50 million. The company has never paid a cash dividend.
- 2020Feb 12, 2021
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2020
IDEXX Laboratories' FY2020 10-K shows a year of strong recovery and growth despite the COVID-19 disruption to veterinary visits in the first half. Total revenue rose 12.5% reported (12.0% organic) to $2.71 billion, and Companion Animal Group (CAG) revenue grew 12.6% to $2.39 billion, with recurring diagnostic revenue (about 78% of consolidated revenue) up 15.6%. Gross margin expanded 130 basis points to 58.0%, and operating income rose 25.6% to $694.5 million, or 25.7% of revenue. Diluted EPS reached $6.71, up from $4.89, aided in part by a one-time Swiss tax reform benefit that lowered the effective tax rate to 12.1%. Operating cash flow was $648.1 million, and the company ended the year with $383.9 million in cash and no borrowings under its $1 billion revolving credit facility. The balance sheet strengthened notably. Stockholders' equity rose to $632.8 million from $177.8 million, reflecting net income and stock issuance, and gross debt of $910.7 million implies a net debt to Adjusted EBITDA ratio of 0.64x, well within the 3.5x covenant. The company issued $200 million of 2.50% senior notes in April 2020, repurchased roughly $180 million of stock, and resumed buybacks in early 2021 after suspending them in the first quarter of 2020. The 2021 capital expenditure plan is $120 million to $140 million. Key risks include the durability of pandemic-driven demand in companion animal care, an unresolved royalty litigation with a $50 million claim against which the company holds a $27.5 million accrual, growing consolidation among veterinary hospital owners and buying groups, foreign currency headwinds (38% of revenue is international), and the expiration of a Netherlands tax ruling at the end of 2022. The COVID-19 PCR testing sales in the Other segment are described as difficult to forecast and may not persist.
- 2019Feb 14, 2020
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2019
IDEXX Laboratories' 2019 10-K shows a year of strong top-line growth and margin expansion. Revenue rose 8.8% reported (10.3% organic) to $2.41 billion, driven by recurring CAG Diagnostics revenue (76% of consolidated revenue), particularly IDEXX VetLab consumables (+12.3%) and reference laboratory services (+10.1%). Gross margin expanded 60 basis points to 56.7%, and operating income grew 12.5% to $552.8 million (23.0% margin). Diluted EPS rose to $4.89 from $4.26, though 2019 results included a roughly $12.2 million after-tax charge tied to the CEO transition. Cash generation remained solid, with operating cash flow of $459.2 million against capital expenditures of $155.0 million. The company repurchased $303.8 million of stock (1.22 million shares) and expanded its share repurchase authorization by 5.0 million shares in February 2020, to a total of 73 million. Leverage is moderate: gross debt to Adjusted EBITDA was 1.45x and net debt to Adjusted EBITDA was 1.32x, well inside the 3.5x covenant. Total stockholders' equity turned positive at $177.8 million after several years of deficits, reflecting accumulated earnings and buybacks. Key watch items include a leadership transition (Jay Mazelsky became CEO in October 2019), a $850 million credit facility that matures in December 2020 and is classified as current, a 2020 capex plan of $140 to $155 million, and continued exposure to currency, since 38% of revenue is international. Management also flagged competitive pressure, consolidation among corporate veterinary hospital owners, and reliance on sole-source suppliers such as Ortho for chemistry slides.
- 2018Feb 15, 2019
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2018
IDEXX Laboratories' FY2018 10-K (filed February 15, 2019) shows a strong year of growth and profitability. Revenue rose 12.4% reported (11.6% organic) to $2.213 billion, driven by recurring diagnostic revenue, which accounted for about 75% of consolidated revenue. Recurring revenue growth was led by IDEXX VetLab consumables (up 19.0% reported) and reference laboratory services (up 13.1%). Gross margin expanded 40 basis points to 56.1%, and operating income grew 19.0% to $491.3 million, with operating margin reaching 22.2%. Diluted EPS rose to $4.26 from $2.94, though the 2018 figure benefited from a lower effective tax rate of 17.6% (versus 30.9% in 2017), partly due to the 2017 Tax Act and share-based compensation tax benefits. The adoption of the New Revenue Standard (ASC 606) on January 1, 2018 materially affected reported results. Management attributed about $58.3 million of 2018 revenue and about $22.9 million of gross profit to the new standard, mainly from accelerated recognition of instrument revenue under the IDEXX 360 volume commitment and up-front loyalty programs. Net income would have been about $18.1 million lower without the standard. Investors should therefore weigh the underlying organic growth rate more heavily than reported growth. The balance sheet remains highly leveraged, with stockholders' deficit of $9.2 million, driven by about $3.8 billion of cumulative share repurchases since 1999. Total debt was about $1.0 billion, including $398.9 million drawn on the $850 million revolver. Gross debt to Adjusted EBITDA was 1.67x and net debt to Adjusted EBITDA was 1.46x, comfortably under the 3.5x covenant. Cash fell sharply to $123.8 million after $597.8 million of financing outflows, largely from debt repayment and $369 million of buybacks. Management guided to a 2019 capital expenditure plan of $160 million to $175 million, including headquarters expansion and a German lab relocation.
- 2017Feb 16, 2018
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2017
IDEXX Laboratories' 2017 10-K shows a company with strong top-line momentum and expanding margins. Revenue rose 10.9% to $1.97 billion (organic growth of 10.4%), driven mainly by the Companion Animal Group (CAG), where recurring diagnostic revenue (about 74% of consolidated revenue) grew 13.3%. Income from operations increased 17.9% to $413.0 million, and the operating margin expanded from 19.7% to 21.0%. Diluted EPS rose to $2.94 from $2.44, helped by a roughly $28 million tax benefit from the adoption of ASU 2016-09 and a lower effective tax rate of 30.9%. The balance sheet remains levered by design. Stockholders' equity is negative at $(53.8) million because of heavy share repurchases ($278 million in 2017), and the company carries $1.26 billion of total debt, mostly a $655 million revolver and senior notes. Management reports a gross debt to Adjusted EBITDA ratio of 2.41x and a net debt ratio of 1.51x, well within the 3.5x covenant. Cash and marketable securities total $472 million. Management also plans to liquidate marketable securities in 2018 to pay down the revolver, and it booked a provisional $48.8 million deemed repatriation tax under the Tax Act. Looking forward, management expects the New Revenue Standard (ASC 606) to add roughly $10 million to 2018 revenue, with an estimated retained-earnings charge below $10 million. The 2018 effective tax rate is guided to 20–21%, and capital expenditures are planned at about $140 million. Key risks disclosed include customer consolidation (corporate hospital chains and buying consortiums), competition, sole-source supplier dependence, currency strength in the U.S. dollar (39% of revenue is international), and the expiration of certain patents. The company has never paid a cash dividend.
- 2016Feb 17, 2017
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2016
IDEXX Laboratories' 2016 10-K shows a company that grew revenue 10.8% to $1.775 billion (11.4% organic growth), with operating income up 16.8% to $350.2 million and diluted EPS of $2.44, up from $2.05. Growth was led by the Companion Animal Group (CAG), where recurring diagnostic revenue (about 72% of consolidated revenue) rose 11.7%, driven by IDEXX VetLab consumables, reference laboratory services, and the new SediVue Dx urinalysis analyzer. Management also highlights the 2015-2016 benefits of the U.S. all-direct sales transition, which is now behind the company, although competitive pressure from former distributors and up-front customer loyalty incentives remain headwinds. Balance sheet and cash flow were strong in operating terms: operating cash flow rose to $334.6 million from $216.4 million, and cash plus marketable securities reached $391.8 million. Stockholders' equity is negative ($108.2 million deficit) because of $1.63 billion in cumulative treasury stock from heavy buybacks ($317 million in 2016). Leverage is moderate on a covenant basis, with gross debt of $1.21 billion (2.66x adjusted EBITDA) and net debt of $816 million (1.80x). Working capital is negative ($89.0 million), largely because the $611 million revolving credit facility is classified as current due to a subjective material adverse event clause. Investors should also note the 39% international revenue exposure and the stronger U.S. dollar drag (about $26 million revenue impact projected for 2017), plus the pending Mars-VCA merger that could shift reference laboratory testing volumes. The company does not pay dividends and has no current plans to do so. Capital returns are instead made through share repurchases, with 3.7 million shares remaining under the 65 million share authorization at year-end. The 2017 outlook includes capital expenditures of about $90 million and an expected $0.12 to $0.16 EPS benefit from the ASU 2016-09 adoption, which will flow through the income statement starting in Q1 2017.
- 2015Feb 17, 2016
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2015
IDEXX Laboratories' FY2015 10-K shows a company that grew revenue 7.8% to $1.60 billion (organic growth of 13.4%, with a 6.2% currency headwind), driven by its Companion Animal Group (CAG), which accounts for roughly 85% of sales. Recurring diagnostic revenue, which includes VetLab consumables, rapid assay kits, and reference lab services, makes up about 72% of consolidated revenue. Operating income rose 15.2% to $299.9 million, though it includes an $8.2 million software impairment, and diluted EPS was $2.05, up from $1.79. The margin story is mixed: gross margin improved to 55.6%, but the company absorbed one-time costs from its shift to an all-direct U.S. sales model that took effect January 1, 2015, and it moved away from distributors that now carry competing products. The balance sheet changed meaningfully. Management aggressively repurchased stock, buying back 5.7 million shares for $406 million, and funded this with debt. Total long-term debt rose to $597 million, with an additional $573 million drawn on the $850 million revolver. Stockholders' equity turned negative at $(84) million, and working capital was negative $35 million. Cash and marketable securities totaled $343 million. Management expects a stronger U.S. dollar to reduce 2016 revenue by about $40 million and diluted EPS by about $0.26. Foreign sales were 39% of revenue. Key risks for investors include the all-direct U.S. transition and loss of distributor coverage, growing competition from lateral-flow rapid tests and Heska, Zoetis, and Antech, consolidation among corporate veterinary hospital owners that may shift purchasing or steer testing to rival reference labs, currency exposure, and rising leverage that is constrained by a 3.5x debt-to-EBITDA covenant.
- 2014Feb 17, 2015
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2014
IDEXX Laboratories' FY2014 10-K shows a company growing revenue 7.9% to $1.486 billion (organic growth of 8.0%) while absorbing a deliberate one-time transition to an all-direct U.S. sales model effective January 1, 2015. Companion Animal Group (CAG) generated 83% of revenue and is driven by recurring diagnostics (about 71% of consolidated revenue), including VetLab consumables, reference lab services and rapid assays. Operating income fell 2.4% to $260.3 million, and operating margin declined to 17.5% from 19.4%, largely because of about $35.3 million in transition impacts (distributor inventory drawdown, ramp-up costs and non-recurring expenses). Management's adjusted operating income was about $295.6 million (19.6% of revenue), up 9.1%. Diluted EPS rose to $3.58 from $3.48, helped by a 7% reduction in diluted share count to 50.8 million shares. The company repurchased $618 million of stock (4.9 million shares) and increased debt, with total long-term debt of $350 million plus a $549 million revolving credit line classified as current. Stockholders' equity fell to $117.6 million from $518.2 million, and working capital turned negative at $(61.5) million. Management expects the all-direct transition to add $50–55 million in annual revenue and $5–8 million in 2015 operating profit, with $15–20 million in extra working capital needs. Key risks include sole-source supplier dependence (such as Ortho chemistry slides), loss of distributor relationships, competition from Antech/VCA, Abaxis, Heska and Zoetis, the strong U.S. dollar (about 28% of revenue is U.S.-manufactured and sold internationally), corporate hospital consolidation, and the approaching expiration of the SNAP immunoassay patents in 2015. The PwC audit opinion was unqualified and internal controls were rated effective.
- 2013Feb 18, 2014
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2013
IDEXX Laboratories' FY2013 10-K shows a company that grew revenue 6.5% to $1.377 billion, with operating income up only 1.6% to $266.8 million, as operating margin compressed from 20.3% to 19.4%. Growth was led by the Companion Animal Group (CAG), whose revenue rose 7.3% to $1.150 billion, driven by recurring diagnostic revenue (VetLab consumables, reference laboratory services, and rapid assays). Diluted EPS rose to $3.48 from $3.17, helped by a 4.0 million-share repurchase ($367.8 million) that cut the diluted share count to about 54.0 million from 56.2 million. Organic growth was about 6.7%, with currency reducing revenue by roughly 0.7%. Margin pressure came from higher sales and marketing and G&A spending, including a $3.9 million loss from a freight payment service provider bankruptcy and higher personnel costs tied to the North American sales force expansion. Balance sheet and capital allocation shifted meaningfully. IDEXX issued $150 million of senior notes in December 2013 (3.94% due 2023 and 4.04% due 2025), and its credit line balance rose to $277 million, so total debt increased sharply. Stockholders' equity fell to $518 million from $636 million because buybacks ($372 million charged to equity) exceeded earnings retention. Cash rose to $279 million, but about $278 million of it sits in foreign subsidiaries, and the company's effective tax rate fell to 28.7% from 31.6%, partly due to a one-time R&D credit recognized in 2013. Management also flagged that the U.S. R&D credit expired again on January 1, 2014, and that interest expense will rise in 2014. The business faces ongoing concentration and competitive risks. Two distributors, Henry Schein (9% of revenue) and MWI (8%), account for a meaningful share of sales, and the FTC consent order limits exclusive distribution arrangements. Corporate hospital consolidation and competitors such as VCA Antech and Abaxis are pressuring the market. Management guided to a 2014 capital expenditure plan of about $80 million and to a roughly $10 million revenue headwind from lower European bovine testing volumes. Overall, the filing describes a company with strong recurring-revenue economics and rising capital returns, but with more leverage, a thinner margin trend, and tax-rate tailwinds that are unlikely to repeat.
- 2012Feb 19, 2013
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2012
IDEXX Laboratories' FY2012 10-K shows a company that grew revenue 6.1% to $1.293 billion (organic growth 6.7%) and expanded operating margin to 20.3% from 19.4%, with diluted EPS rising 14% to $3.17. Growth was led by the Companion Animal Group (CAG), which rose 7.3% to $1.07 billion, driven by reference laboratory services (+8.9%), VetLab consumables (+9.0%) and practice management (+11.3%). LPD was the weak spot, with revenue down 7.9% on EU BSE testing reductions, and management now estimates BSE product revenue at under $10 million. Cash generation and balance sheet are solid. Operating cash flow was $230.3 million, cash rose to $224.0 million, and total debt fell to $214.5 million from $246.4 million. The company spent $132.3 million repurchasing 1.5 million shares, leaving 2.9 million shares under its 48 million-share authorization. IDEXX has never paid a cash dividend and has no present intention to do so. Capital spending is planned at about $75 million for 2013, including a headquarters expansion. Key risks include the February 2013 FTC consent order, which limits exclusive distribution to two of the three largest U.S. distributors and changes the MWI relationship from January 2013. Other risks are concentration in Butler Schein (9% of revenue), customer consolidation through corporate hospital owners and buying groups, sole-source supply dependence on Ortho for chemistry slides, and about 41% of revenue from outside the U.S. The new Westbrook administrative building is expected to be substantially complete in late 2013, and the 2013 R&D tax credit reinstatement should lower the effective tax rate by roughly 2 points.
- 2011Feb 17, 2012
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2011
IDEXX Laboratories' FY2011 Form 10-K shows a company that grew revenue 10.4% to $1.219 billion, with net income attributable to stockholders of $161.8 million, or $2.78 diluted EPS, up from $2.37 in 2010. Growth was broad-based: Companion Animal Group (CAG) revenue rose 10.4% to $999.7 million, led by reference laboratory services (+13.4%) and instruments and consumables (+11.4%), while organic growth was 7.8% after adjusting for currency (+2.4%) and acquisitions (+0.2%). Gross margin expanded to 53.0% from 52.4%, and operating margin improved to 19.4% from 18.5%, driven by manufacturing cost improvements and higher-margin mix. Cash generation was strong, with operating cash flow of $220.7 million, but the balance sheet became more levered. The company spent $255.5 million repurchasing 3.4 million shares, and borrowings under its $300 million revolving Credit Facility rose to $243.0 million, which is classified as a current liability. Working capital fell to $87.3 million from $175.5 million, and total debt increased to $246.4 million from $133.3 million. The company also made acquisitions, most notably the RADIL bioresearch laboratory for $43.0 million, and plans a 2012 capital expenditure budget of about $60 million. Key risks include a pending FTC investigation into companion animal sales practices, which the company believes is nearing a conclusion and could lead to prospective remedies but no financial penalties; customer concentration, with Butler Schein accounting for 9% of revenue; dependence on sole-source suppliers, including Ortho for chemistry slides; and exposure to a strong U.S. dollar, with about 43% of revenue generated internationally. The company has never paid a cash dividend.
- 2010Feb 22, 2011
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2010
IDEXX Laboratories' 10-K for fiscal 2010 (filed February 22, 2011) shows a company that grew revenue 7.0% to $1.103 billion, with 6.3% organic growth, and expanded operating income 15.9% to $203.9 million. Growth was led by the Companion Animal Group (CAG), which generated $905.7 million (82% of revenue) and drove most of the increase through reference laboratory services (+10.5%), practice information systems and digital radiography (+15.6%), and instruments and consumables (+6.5%). Rapid assay sales were roughly flat, and the Water and Livestock & Poultry Diagnostics segments grew modestly. Gross margin improved to 52.4% from 51.0%, while operating expenses held at 34.0% of revenue. Diluted EPS rose to $2.37 from $2.01. Cash generation and capital returns were strong. Operating cash flow was $178.8 million, and cash and investments ended the year at $156.9 million, up from $106.7 million. The company repurchased 2.5 million shares for $143.1 million, and total debt was $133.3 million, almost entirely the $129.0 million Credit Facility, which carries a leverage covenant of 3-to-1. Management expects 2011 capital expenditures of about $45 million and says it has never paid a cash dividend and has no plans to do so. Key risks flagged in the filing include the U.S. Federal Trade Commission investigation into companion animal pricing and marketing practices and a parallel U.K. Office of Fair Trading inquiry, both of which management believes do not violate antitrust law. Other risks include customer concentration (Butler Schein accounted for 9% of revenue), reliance on sole-source suppliers such as Ortho for chemistry slides, the expiry of a key FIV/FeLV patent in June 2009, weak pet-visit volumes from the economy, and rising competition from Abaxis and Antech. International sales accounted for 41% of revenue.
- 2009Feb 19, 2010
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2009
IDEXX Laboratories' FY2009 10-K shows a company that grew revenue modestly in a weak economy while sustaining solid profitability and returning capital to shareholders. Total revenue rose 0.7% to $1,031.6 million (about 2.4% lower on a currency- and acquisition-adjusted basis), while operating income increased 2.0% to $176.0 million and diluted EPS rose 7.5% to $2.01. Growth was concentrated in the Companion Animal Group (CAG), where the Catalyst Dx chemistry analyzer drove instrument and consumables sales, offset by weaker rapid assay pricing, reduced patient visits, and the loss of higher-margin pharmaceutical revenue following the 2008 divestiture. Gross margin compressed slightly to 51.0% from 51.7%, and Water and Other segments were the bright spots on margin and profit. Balance sheet and cash flow improved meaningfully. Operating cash flow rose to $175.0 million from $143.3 million, and total debt fell from $156.5 million to $123.9 million, with the revolver balance dropping to $118.8 million. IDEXX repurchased $83.1 million of stock (1.9 million shares) and ended the year with $106.7 million in cash. Capital spending of $49.4 million was lower than 2008 as the Westbrook, Maine headquarters expansion moves toward completion in 2011; 2010 capex is planned at about $45 million. Key investor watch items include an FTC investigation (announced January 2010) into companion animal pricing and distribution practices, concentration risk with distributors (Butler Schein Animal Health is 7% of revenue after the December 2009 merger), single-site manufacturing in Westbrook, Maine, and the expected expiration of the SNAP FIV/FeLV patent in June 2009 that could pressure those product margins. Management also flagged near-term gross margin pressure from higher instrument placements and the phase-out of rapid assay Practice Developer rebates, and an EU BSE testing age change that will reduce post-mortem test volumes.
- 2008Feb 20, 2009
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2008
IDEXX Laboratories' fiscal 2008 10-K shows a company that grew revenue 11% to $1.024 billion and expanded operating income 27% to $172.5 million, with net income up 24% to $116.2 million and diluted EPS of $1.87 (up from $1.46). Growth was led by the Companion Animal Group (CAG), which rose 11% to $834 million on higher instrument and consumable sales, the launch of the Catalyst Dx and SNAPshot Dx analyzers, and strong rapid assay and reference laboratory volumes. Gross margin improved to 51.7% from 50.2%, though management flagged near-term pressure from higher instrument placements as Catalyst Dx penetrates the base. Investors should weigh several headwinds for 2009: the loss of Cryptosporidium testing revenue in England and Wales (Filta-Max sales of $2.8 million), a roughly 30% reduction in the EU's BSE testing population affecting the Production Animal Segment, expiration of the FIV patent in June 2009 that will pressure SNAP FIV/FeLV margins, and the wind-down of the veterinary pharmaceutical business after the Q4 2008 sale. Balance sheet leverage rose: total debt climbed to $156.5 million from $78.7 million, largely to fund share repurchases ($132.3 million in 2008) and the Westbrook, Maine facility expansion. Cash flow from operations was $143.3 million, and the company disclosed no material exposure from the Cyntegra antitrust suit, which was dismissed at the trial level and is on appeal. Overall, the filing portrays a financially healthy, growing company with strong margins and heavy capital return, but with visible 2009 revenue headwinds from regulatory and patent changes and a notable dependence on a single distributor (Butler Animal Health Supply, 8% of revenue) and on sole-source suppliers such as Ortho for chemistry slides.
- 2007Feb 27, 2008
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2007
IDEXX Laboratories' 2007 10-K shows a company growing revenue 25% to $922.6 million, driven by acquisitions (about 8 points of growth) and a 3-point currency tailwind, with organic growth around 14%. Net income was essentially flat at $94.0 million, rising only 0.3%, as operating income grew 6% to $136.2 million. Operating margin fell to 14.8% from 17.3%, reflecting a $10.1 million Navigator® write-down, higher share-based compensation, and the mix shift toward lower-margin laboratory services and instruments. Diluted EPS was $1.46 versus $1.42 in 2006. The most significant balance-sheet change is leverage. Short-term debt rose to $72.2 million under a revolving credit facility used to fund acquisitions (including Vita-Tech, Pourquier, and the Osmetech Critical Care Division) and share repurchases of $118.8 million. Cash and investments fell to $60.4 million, working capital dropped to $82.3 million from $177.5 million, and the company increased its credit facility to $200 million in February 2008. Operating cash flow was $135.1 million, but capital spending is set to climb with roughly $140 million planned for the Westbrook, Maine expansion through 2011. Investors should weigh several risks. Over 40% of revenue is international. A large pharmaceutical product, about $15.4 million of CAG revenue, could have to be discontinued once FDA approves a competing product or its raw-material inventory runs out in late 2008 or early 2009. Filta-Max® sales of $2.8 million in England and Wales are at risk after 2009. The Catalyst Dx® launch is expected to shift more VetLab revenue toward instrument sales, which carry lower margins. Management also flagged dependence on Ortho for VetTest® slides and reliance on a few distributors, with Butler Animal Health at 8% of revenue.
- 2006Mar 1, 2007
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2006
IDEXX Laboratories' 2006 Form 10-K shows a company that grew revenue 16% to $739.1 million and net income 20% to $93.7 million (diluted EPS $2.84, up from $2.30). Growth was driven mainly by the Companion Animal Group (CAG), which rose 16% to $606.3 million on higher instrument and consumables volume, reference laboratory acquisitions, and strong practice-level demand for SNAP 4Dx and VetTest slides. Gross margin held roughly flat at 51.3%. Operating margin fell to 17.3% from 18.1%, largely because adopting SFAS 123(R) added about $9.0 million of share-based compensation to operating expenses, and an unallocated corporate cost line rose sharply. The 28.4% effective tax rate, down from 34.2%, was helped by a $3.7-point benefit from resolving an IRS audit, so the earnings jump is partly flattered by one-time items. The balance sheet and cash flow picture is more mixed. Operating cash flow fell to $109.8 million from $116.6 million, partly because $9.4 million of tax benefits moved to financing cash flows and inventories rose $25.7 million. Cash and short-term investments declined to $96.7 million, and inventories increased to $96.0 million. Management used cash for buybacks ($105.7 million of stock repurchased in 2006) and acquisitions. Subsequent to year-end, IDEXX bought the Critical Care Division of Osmetech plc for about $45 million, entering the human point-of-care electrolyte and blood gas market, and it agreed to acquire Institut Pourquier. It also arranged a $125 million short-term credit facility, which it expected to replace with a longer-term facility before June 2007. Management plans a major product transition, with Catalyst Dx and SNAPshot Dx both targeted for January 2008. Key risks for investors include concentration in U.S. distributors (Butler Animal Health Supply was 9% of 2006 revenue), roughly $169 million of purchase obligations, dependence on single-source suppliers including Ortho for VetTest slides, a near-term revenue threat from the U.K. Cryptosporidium testing rule change (about $2.9 million of Filta-Max sales), and the eventual loss of an FDA-discretion pharmaceutical product (about $11.9 million of 2006 revenue). The company has never paid a cash dividend, and it reported no material legal proceedings.
- 2005Mar 10, 2006
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2005
IDEXX Laboratories' fiscal 2005 10-K shows a company that grew revenue 16% to $638.1 million, led by its Companion Animal Group (CAG), which rose 16% to $520.8 million on strong growth in reference laboratory services (up 32%, largely from acquisitions) and instruments and consumables (up 10%). Operating income rose 7% to $115.3 million, but operating margin compressed from 19.7% to 18.1%, reflecting acquisition integration costs, amortization of acquired intangibles, and continued investment in sales, customer service and marketing. Diluted EPS increased 5% to $2.30 despite a higher effective tax rate of 34.2% (versus 29.7% in 2004, which benefited from a one-time IRS audit resolution), and net income was roughly flat at $78.3 million. The balance sheet and cash flow picture is solid. Operating cash flow rose to $116.6 million, and the company repurchased about 1.99 million shares for $123.8 million, reducing the share count meaningfully (weighted average diluted shares fell from 35.8 million to 34.1 million). Cash and short-term investments declined to $132.7 million, and stockholders' equity fell to $369.0 million because buybacks exceeded earnings. Debt is negligible at $0.55 million. Looking ahead, investors should weigh several items: share-based compensation expensing under SFAS 123(R) begins in 2006 and will pressure margins; the company's VetTest slide supply is concentrated with Ortho and carries a $92.7 million minimum purchase commitment through 2010; the next-generation chemistry analyzer is not expected before late 2007; and roughly 34% of revenue is international. Distributor purchasing patterns and the consolidation of U.S. distributors (two of which now represent 10% of revenue) add quarterly volatility, and the company reports no material legal proceedings.
- 2004Mar 15, 2005
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2004
IDEXX Laboratories' FY2004 10-K shows a strong year driven by its Companion Animal Group (CAG), which generated 82% of revenue. Total revenue rose 15.4% to $549.2 million (12.3% excluding currency effects), gross margin expanded to 50.8% from 48.4%, and operating income grew 34% to $108.0 million, lifting operating margin to 19.7% from 16.9%. Diluted EPS reached $2.19 versus $1.59 in 2003, and net income climbed to $78.3 million. Growth was broad-based, with laboratory and consulting services (+25%), instruments and consumables (+12%), and rapid assays (+13%) leading, though management noted that some 2004 comparisons were flattered by lower distributor inventory levels in 2003 and favorable currency movements. The balance sheet and capital allocation picture is more mixed. Cash and investments fell to $157.0 million from $255.8 million because the company spent $128.8 million repurchasing about 2.4 million shares and $53.9 million on acquisitions, including Vet Med Lab in Germany, Bommeli AG in Switzerland, and an Ohio laboratory. Goodwill and intangibles nearly doubled to $124.5 million, and stockholders' equity declined to $397.7 million. Operating cash flow remained robust at $95.4 million, though it fell from $117.2 million in 2003. Management guided to slower growth in pharmaceuticals and Water in 2005, a margin headwind from expensing stock compensation starting July 2005 (about $8.0 million pre-tax for 2005), and integration costs from recent acquisitions. Key risk areas for investors include concentration in distributor purchasing patterns, a fixed-price minimum purchase commitment of $131.8 million for VetTest slides from Ortho through 2010, sole-source supply dependencies, the pending FDA review of the tilmicosin product, and the dependence of the Food Diagnostics Group on international BSE testing demand. The company reported no material legal proceedings and effective internal controls, with PricewaterhouseCoopers issuing an unqualified opinion.
- 2003Mar 3, 2004
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2003
IDEXX Laboratories' 2003 10-K shows a company that grew revenue 15% to $476.0 million and net income 26% to $57.1 million (diluted EPS $1.59, up from $1.30). Growth was led by the Companion Animal Group (CAG), which rose 18% to $384.4 million on strong LaserCyte hematology instrument sales, rapid assays, and laboratory services. Operating income rose 22% to $80.4 million, and operating margin widened to 16.9% from 15.9%, helped by a higher gross margin of 48.4%. Part of the growth reflects a favorable comparison with 2002, when distributor inventories were reduced, and about 4 points of revenue growth came from currency effects. The balance sheet strengthened, with cash and investments of $255.8 million and debt of only $0.5 million. Operating cash flow reached $117.2 million, and the company repurchased about $36 million of stock. Management also flagged risks, including a $7.4 million non-cash write-down tied to ending development of an alternative chemistry analyzer after a new supply agreement with Ortho, a dependence on Ortho for VetTest slide purchases with minimum commitments of $170.4 million through 2010, and rising heartworm test competition as rivals re-entered the market. The company also disclosed a litigation dispute with its computed radiography supplier, though it said it is not party to any material legal proceedings. For investors, the key questions are whether the instrument and laboratory growth can be sustained, whether competition in heartworm testing erodes rapid assay pricing, and whether the Ortho dependency and the pipeline of pharmaceutical products (NAVIGATOR approved in November 2003) can diversify the revenue base over time.
- 2002Mar 20, 2003
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2002
IDEXX Laboratories' 2002 10-K shows a company that grew revenue 7% to $412.7 million and net income 21% to $45.4 million (diluted EPS $1.30, up from $1.09). Growth came mainly from the Companion Animal Group (CAG), which generated about 79% of sales and grew 6% to $326.9 million, while the Food and Environmental Group (FEG) grew 10% to $85.8 million. Gross margin held flat at 47%, and operating income rose 16% to $65.8 million, helped by the adoption of SFAS 142 (which ended goodwill amortization) and a $0.7 million reversal of an Ortho slide contract loss reserve, partly offset by $3.4 million in CEO succession charges and higher foreign exchange hedge losses. The balance sheet strengthened, with cash and investments of $162.8 million, working capital of $213.4 million, and total debt reduced to under $1 million. Operating cash flow was $103.3 million, and the company repurchased 1.0 million shares for $29.8 million. Management expects no dividends, and capital spending of about $19.8 million is planned for 2003. Investors should watch several risks: a $232.4 million minimum purchase obligation for VetTest slides from Ortho, a nitazoxanide pharmaceutical awaiting FDA approval with $8.4 million of inventory at risk, a LaserCyte hematology launch that will raise warranty costs, heavy reliance on distributor inventory levels, and a 29% international revenue mix that adds currency exposure (a 10% dollar strengthening would cut operating income by about $5.3 million after hedges).
- 2001Mar 21, 2002
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2001
IDEXX Laboratories' 2001 10-K shows a company with steady, profitable growth but slowing top-line momentum. Revenue rose 5% to $386.1 million in 2001 (from $367.4 million), while net income climbed 3% to $37.6 million and diluted EPS reached $1.09 (up from $1.02). Gross margin held near 47%, and operating income grew 6% to $56.6 million. Growth was concentrated in the Companion Animal Group (CAG, +4% to $308.0 million) and the Food and Environmental Division (FED, +9% to $78.0 million), with water testing and veterinary reference labs as the main drivers. Management acknowledges that the growth rate of certain products has declined over several years, and CAG's gross margin slipped to 45% due to fixed-cost under-absorption from delayed product launches. The balance sheet strengthened, with stockholders' equity rising to $301.7 million and operating cash flow of $46.4 million funding $17.4 million of capex and $13.0 million of share buybacks. Cash and short-term investments were $79.6 million, plus $21.0 million in long-term investments, and the company carries only $8.4 million of notes payable. Inventory rose sharply to $86.2 million, driven by VetTest slide purchase commitments, LaserCyte hematology development costs, and $8.6 million of nitazoxanide raw materials tied to a pending FDA approval. Total unconditional purchase obligations of $299.4 million through 2010 represent a notable fixed commitment. Key forward-looking items include the planned second-half 2002 launch of the LaserCyte hematology system (which management expects to raise warranty expense significantly), the FDA review of nitazoxanide, a CEO transition to Jonathan Ayers in January 2002 with a roughly $3.0 million related charge, and the adoption of SFAS 142, which will eliminate about $4.3 million of goodwill amortization in 2002 and requires an impairment review. Management does not currently expect an impairment charge.
- 2000Mar 29, 2001
IDEXX Laboratories Annual Report, Year Ended Dec 31, 2000
IDEXX Laboratories, Inc. (IDXX) presents its 2000 Form 10-K, detailing robust performance primarily driven by its Companion Animal Group (CAG). CAG, encompassing veterinary diagnostics, pharmaceuticals, and informatics, saw revenue growth fueled by increased reference laboratory services, consumables, and test kits. Despite a slight dip in gross margin percentage due to a higher mix of lower-margin services, overall operating expenses remained controlled, largely due to strategic expense management and the ongoing development of its internet platform for animal health professionals. The Food and Environmental Division (FED) experienced a revenue decline, primarily attributed to the divestiture of its food microbiology testing business. However, gross margins within FED improved significantly due to the disposal of the lower-margin business and growth in higher-margin water testing products. The company continues to invest in research and development, focusing on new diagnostic systems, enhanced information solutions, and novel veterinary therapeutics, positioning itself for future growth and innovation in the animal health sector.
- 1999Mar 29, 2000
IDEXX Laboratories Annual Report, Year Ended Dec 31, 1999
IDEXX Laboratories' 10-K for fiscal 1999 shows a company that returned to profitability after a difficult 1997-1998 period. Revenue rose 11% to $356.2 million (from $319.9 million), gross profit grew to $174.1 million, and operating income swung to $46.8 million from an $8.1 million loss in 1998, which had included a $37.2 million in-process R&D write-off tied to the Blue Ridge Pharmaceuticals acquisition. Net income was $32.6 million, or $0.82 diluted EPS, versus a $15.2 million loss in 1998. Sales and marketing and G&A expenses were held flat-to-down, while R&D rose to $27.3 million, reflecting investment in the animal health pharmaceuticals pipeline and the VetConnect internet business. The balance sheet remains conservative but shrank in 1999 because of capital return. The company repurchased 3.9 million shares for $64.2 million under a six-million-share authorization, reducing stockholders' equity to $284.3 million and cash and short-term investments to $105.4 million. Management states that current liquidity will be sufficient for the foreseeable future. Total debt was reduced to $3.5 million. Investors should weigh several risks: a securities class action (Rose v. Shaw) is being settled via a memorandum of understanding; a separate SA Scientific suit seeks $32 million in damages and is being contested; the company faces single-source supply dependencies (Ortho slides, Tokyo Parts analyzers, Becton hematology components); and competitive pressure is increasing in canine heartworm diagnostics. The company also disposed of its food microbiology business in late 1999 and early 2000 to sharpen its focus on veterinary markets, which generate roughly 69% of revenue.